Nektar Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1990-01-01
- Employees
- 137
- Market Cap
- $230M
- Website
- http://www.nektar.com
- Introduction
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cance...
A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 296
- Registration Number
- NCT01619839
- Locations
- 🇺🇸
Investigator Site - Louisville, Louisville, Kentucky, United States
🇺🇸Investigator Site - Garden Grove, Garden Grove, California, United States
🇺🇸Investigator Site - Coral Gables, Coral Gables, Florida, United States
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
- Conditions
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 852
- Registration Number
- NCT01492101
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇨🇦Odette Cancer Centre OCC Clinical Research, Toronto, Ontario, Canada
🇧🇪Universtair Ziekenhuis Antwerpen, Edegem, Belgium
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
- Conditions
- Interventions
- First Posted Date
- 2011-10-21
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT01457118
- Locations
- 🇺🇸
Investigator Site - Minneapolis, Minneapolis, Minnesota, United States
🇺🇸Investigator Site - Los Angeles, Los Angeles, California, United States
🇺🇸Investigator Site - Cleveland, Cleveland, Ohio, United States
NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 83
- Registration Number
- NCT00856375
- Locations
- 🇮🇳
Investigator Site - Ahmedabad, Ahmedabad, Gujarat, India
🇮🇳Investigator Site - Kochi, Kochi, Kerata, India
🇺🇸Investigator Site - Burbank, Burbank, California, United States
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 178
- Registration Number
- NCT00806156
- Locations
- 🇬🇧
Investigator Site - Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom
🇧🇪Investigator Site - Gent, Gent, Belgium
🇺🇸Investigator Site - Higland, Highland, California, United States
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT00802945
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪GasthuisZusters Antwerpen, Wilrijk, Belgium
🇺🇸Pharma Resource, East Providence, Rhode Island, United States
NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
- Conditions
- Interventions
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT00598975
- Locations
- 🇺🇸
Investigator Site - Scottsdale, Scottsdale, Arizona, United States
🇺🇸Investigator Site - Tyler, Tyler, Texas, United States
🇺🇸Investigator Site - Louisville, Louisville, Kentucky, United States